androgen receptor antagonist TQB3720
Term · Oncology and biomedicine · MLC-T-ONC-010068
An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist TQB3720 specifically targets and binds to the AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells.
| Identifier | MLC-T-ONC-010068 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | AR antagonist TQB3720 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010068",
"term": "androgen receptor antagonist TQB3720",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist TQB3720 specifically targets and binds to the AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells.",
"synonyms": [
"AR antagonist TQB3720"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/androgen-receptor-antagonist-tqb3720/"
}
Record 1,076 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.